{"component": "definition", "props": {"groups": [{"samples": [{"hash": "76LvfA5Ov5J", "uri": "/contracts/76LvfA5Ov5J#lead-compounds", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}, {"hash": "62OnBgLcliT", "uri": "https://investors.vrtx.com/static-files/3320a35d-a1d7-4ecf-ae63-999be5f889aa", "label": "investors.vrtx.com", "score": 9.965092659, "published": false}], "snippet": "means not more than two Compounds from each Program \u2014 Primary or Alternate - for which a Testing Request is delivered, none of which are a Development Candidate, which meet the following criteria: (i) the Compound(s) have been selected by Vertex from the Primary Program and/or the Alternate Program, as relevant to the Testing Request (assuming CFFT has not terminated the Alternate Program under the provisions of Section 10.5.3 hereof); (ii) each Compound will be representative of those Compounds in each Program which Vertex believes to be the most promising as potential Drug Products; and", "size": 5, "snippet_links": [{"key": "testing-request", "type": "definition", "offset": [89, 104]}, {"key": "development-candidate", "type": "clause", "offset": [139, 160]}, {"key": "primary-program", "type": "definition", "offset": [255, 270]}, {"key": "alternate-program", "type": "definition", "offset": [282, 299]}, {"key": "the-testing", "type": "definition", "offset": [316, 327]}, {"key": "the-provisions-of-section", "type": "clause", "offset": [398, 423]}, {"key": "drug-products", "type": "definition", "offset": [577, 590]}], "hash": "74ef9ba9ea36b574cb30a26fc711fcf7", "id": 1}, {"samples": [{"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#lead-compounds", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816562653, "published": true}, {"hash": "7b4DJrnOvC2", "uri": "/contracts/7b4DJrnOvC2#lead-compounds", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.3874053955, "published": true}], "snippet": "means not more than two Compounds from each Program \u2014 Primary or Alternate\u2014for which a Testing Request is delivered, none of which are a Development Candidate, which meet the following criteria: (i) the Compound(s) have been selected by Vertex from the Primary Program and/or the Alternate Program, as relevant to the Testing Request (assuming CFFT has not terminated the Alternate Program under the provisions of Section 10.5.3 hereof); (ii) each Compound will be representative of those Compounds in each Program which Vertex believes to be the most promising as potential Drug Products; and (iii) each Compound shall have been previously tested by Vertex, in vitro, as to potential efficacy and potency in CF, and the results of that testing shall have been provided to CFFT. Vertex and CFFT acknowledge that commercially available assays for the testing of Lead Compounds may yield results which are less robust than the results obtained by Vertex in its own proprietary assays. The parties also acknowledge that the transfer of Vertex\u2019s proprietary assays to an Agreed Lab may be difficult, and the results less than satisfactory, without a commitment of substantial time and effort by Vertex which, if undertaken, may adversely impact the progress of the Research Program. Therefore, the parties agree that Vertex\u2019s responsibility for the testing provided under this Section 2.10 shall be limited as follows: (a) Vertex will cooperate with CFFT in the selection of an Agreed Lab as soon as practicable following the Effective Date, as may be requested by CFFT, and thereafter will assist in the determination whether commercially available assays conducted by the Lab are likely to provide satisfactory results; (b) Vertex will provide the Lab with requisite amounts of each Lead Compound, in connection with formal Testing Requests from CFFT as provided above, and up to three additional Compounds from each of the Primary or Alternate Programs, out of any supplies which Vertex may have on hand, the chemical structures of which have been published by Vertex in peer-reviewed journals or through posters or presentations at scientific conferences, which the Agreed Lab may use for control purposes; (c) Vertex will provide telephone consulting to appropriate representatives of the Agreed Lab concerning applicable assay methodology; (d) if the parties conclude that conventional testing will not yield adequate results, and upon the formal written request of CFFT rendered with due regard to [***] to establish an assay based on proprietary protocols from Vertex, Vertex will provide its proprietary assay protocol to the Agreed Lab sufficiently in advance of any testing provided for in this Section 2.10 to accommodate such testing, under provisions of confidentiality, restricted access and non-use (for other than testing hereunder), and will ensure that appropriate Vertex representatives are available by telephone from time to time to answer questions and otherwise assist the Agreed Lab representatives in their efforts to establish Vertex\u2019s proprietary assay. Vertex shall in no event be responsible for any failure by the Agreed Lab to establish an effective assay using Vertex\u2019s protocols, nor shall any time periods provided herein for action by CFFT be extended by reason of any such failure.", "size": 5, "snippet_links": [{"key": "testing-request", "type": "definition", "offset": [87, 102]}, {"key": "development-candidate", "type": "clause", "offset": [137, 158]}, {"key": "primary-program", "type": "definition", "offset": [253, 268]}, {"key": "the-testing", "type": "definition", "offset": [314, 325]}, {"key": "the-provisions-of-section", "type": "clause", "offset": [396, 421]}, {"key": "drug-products", "type": "definition", "offset": [575, 588]}, {"key": "in-vitro", "type": "definition", "offset": [659, 667]}, {"key": "commercially-available", "type": "definition", "offset": [812, 834]}, {"key": "transfer-of", "type": "clause", "offset": [1021, 1032]}, {"key": "less-than-satisfactory", "type": "clause", "offset": [1112, 1134]}, {"key": "a-commitment", "type": "definition", "offset": [1144, 1156]}, {"key": "time-and-effort", "type": "clause", "offset": [1172, 1187]}, {"key": "the-research-program", "type": "clause", "offset": [1257, 1277]}, {"key": "the-parties-agree-that", "type": "clause", "offset": [1290, 1312]}, {"key": "responsibility-for", "type": "clause", "offset": [1322, 1340]}, {"key": "cooperate-with", "type": "clause", "offset": [1431, 1445]}, {"key": "selection-of", "type": "clause", "offset": [1458, 1470]}, {"key": "as-soon-as-practicable", "type": "definition", "offset": [1485, 1507]}, {"key": "following-the-effective-date", "type": "clause", "offset": [1508, 1536]}, {"key": "requested-by", "type": "clause", "offset": [1548, 1560]}, {"key": "the-determination", "type": "clause", "offset": [1597, 1614]}, {"key": "to-provide", "type": "definition", "offset": [1685, 1695]}, {"key": "provide-the", "type": "clause", "offset": [1734, 1745]}, {"key": "in-connection-with", "type": "clause", "offset": [1796, 1814]}, {"key": "formal-testing", "type": "clause", "offset": [1815, 1829]}, {"key": "additional-compounds", "type": "definition", "offset": [1884, 1904]}, {"key": "alternate-programs", "type": "clause", "offset": [1933, 1951]}, {"key": "on-hand", "type": "definition", "offset": [1995, 2002]}, {"key": "scientific-conferences", "type": "clause", "offset": [2132, 2154]}, {"key": "to-appropriate", "type": "clause", "offset": [2252, 2266]}, {"key": "representatives-of-the", "type": "clause", "offset": [2267, 2289]}, {"key": "the-formal", "type": "clause", "offset": [2438, 2448]}, {"key": "written-request", "type": "definition", "offset": [2449, 2464]}, {"key": "due-regard", "type": "definition", "offset": [2487, 2497]}, {"key": "to-establish", "type": "definition", "offset": [2507, 2519]}, {"key": "based-on", "type": "clause", "offset": [2529, 2537]}, {"key": "in-advance", "type": "clause", "offset": [2655, 2665]}, {"key": "provisions-of-confidentiality", "type": "clause", "offset": [2750, 2779]}, {"key": "restricted-access", "type": "definition", "offset": [2781, 2798]}, {"key": "by-telephone", "type": "clause", "offset": [2917, 2929]}, {"key": "from-time-to-time", "type": "clause", "offset": [2930, 2947]}, {"key": "answer-questions", "type": "clause", "offset": [2951, 2967]}, {"key": "assist-the", "type": "clause", "offset": [2982, 2992]}, {"key": "in-no-event", "type": "clause", "offset": [3091, 3102]}, {"key": "responsible-for", "type": "clause", "offset": [3106, 3121]}, {"key": "failure-by-the", "type": "clause", "offset": [3126, 3140]}, {"key": "time-periods", "type": "definition", "offset": [3224, 3236]}, {"key": "action-by", "type": "clause", "offset": [3257, 3266]}], "hash": "d9404b276b9a8a1955b1770d65bc7689", "id": 2}, {"samples": [{"hash": "aBqXojowaKh", "uri": "https://oshc.dole.gov.ph/wp-content/uploads/2020/02/OSH-Standards-2020-Edition.pdf", "label": "oshc.dole.gov.ph", "score": 10.5181379318, "published": false}, {"hash": "erA3uL7uOpv", "uri": "https://oshc.dole.gov.ph/wp-content/uploads/2020/12/OSH-Standard-2020.pdf", "label": "oshc.dole.gov.ph", "score": 10.4688568115, "published": false}, {"hash": "csYhnOeyJq0", "uri": "https://bwc.dole.gov.ph/images/Downloads/OSH-Standards-Amended-1989.pdf", "label": "bwc.dole.gov.ph", "score": 6.6714577675, "published": false}], "snippet": "means any organic or inorganic derivatives of lead.", "size": 4, "snippet_links": [], "hash": "d87b2592cf156e277071986b08da5544", "id": 3}, {"samples": [{"hash": "jYF7ykFQhOH", "uri": "/contracts/jYF7ykFQhOH#lead-compounds", "label": "Assignment and License Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "kjI5rqQbulX", "uri": "https://ir.syntheticbiologics.com/all-sec-filings/content/0000921895-97-000960/0000921895-97-000960.pdf", "label": "ir.syntheticbiologics.com", "score": 7.6981520653, "published": false}], "snippet": "means those compounds which have [Text Omitted] as determined and selected by NEWCO from the NCEs.", "size": 4, "snippet_links": [{"key": "by-newco", "type": "clause", "offset": [75, 83]}], "hash": "6a9130167d15a4d368805ea40e0d3ade", "id": 4}, {"samples": [{"hash": "azgXxunKQN0", "uri": "/contracts/azgXxunKQN0#lead-compounds", "label": "Collaborative Research and License Agreement (Combichem Inc)", "score": 18.0, "published": true}, {"hash": "1PZFeNamXLD", "uri": "/contracts/1PZFeNamXLD#lead-compounds", "label": "Collaborative Research and License Agreement (Imclone Systems Inc/De)", "score": 18.0, "published": true}], "snippet": "means a compound (or compounds) which\n(a) is selected from an Active Compound(s) by the RMC under the Research Program, or\n(b) is derived from Active Compound(s) and is selected by the RMC. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.", "size": 4, "snippet_links": [{"key": "the-research-program", "type": "clause", "offset": [98, 118]}, {"key": "pursuant-to-a", "type": "definition", "offset": [234, 247]}, {"key": "request-for-confidential-treatment", "type": "definition", "offset": [248, 282]}, {"key": "the-commission", "type": "clause", "offset": [309, 323]}], "hash": "021fb1b4604217c35ebab430b415c797", "id": 5}, {"samples": [{"hash": "7hMGGkEsXt0", "uri": "/contracts/7hMGGkEsXt0#lead-compounds", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 36.5756340027, "published": true}, {"hash": "7AmF4p653oI", "uri": "/contracts/7AmF4p653oI#lead-compounds", "label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "score": 27.4394245148, "published": true}, {"hash": "3jW9vRfQShD", "uri": "/contracts/3jW9vRfQShD#lead-compounds", "label": "Strategic Collaboration Agreement (Isis Pharmaceuticals Inc)", "score": 26.8535251617, "published": true}], "snippet": "has the meaning set forth in Section 1.14.1.", "size": 3, "snippet_links": [], "hash": "1b782c0c4152fc3e1029b2c6521cc40d", "id": 6}, {"samples": [{"hash": "iWpBoVKfG7H", "uri": "/contracts/iWpBoVKfG7H#lead-compounds", "label": "Collaborative Research and License Agreement (Combichem Inc)", "score": 18.0, "published": true}], "snippet": "means a compound (or compounds) which\n(a) is selected from an Active Compound(s) by *** under the Research Program, or\n(b) is derived from Active Compound(s) and is selected by ***", "size": 3, "snippet_links": [{"key": "the-research-program", "type": "clause", "offset": [94, 114]}], "hash": "cf8377745d6a982ca661a5becaca483c", "id": 7}, {"samples": [{"hash": "8AuFwC65xIW", "uri": "/contracts/8AuFwC65xIW#lead-compounds", "label": "Collaboration and License Agreement (Neurocrine Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "7aGLcmG714V", "uri": "https://neurocrine.gcs-web.com/static-files/0456a7b5-8b4b-4c1f-bedb-edf188bae0a6", "label": "neurocrine.gcs-web.com", "score": 10.0704994202, "published": false}], "snippet": "means those Compounds (i) [***], (ii) that meet the criteria set forth on Exhibit B hereto and (iii) that are selected by the Steering Committee or Wyeth-Ayerst in accordance with Article Six, provided, however, that Lead Compounds shall specifically exclude any Compounds [***]. Notwithstanding the foregoing, for purposes of calculating Net Sales and determining License Fees and Royalty payments under this Agreement, a Lead Compound together with all complexes, mixtures and other combinations, prodrugs, metabolites, enantiomers, salt forms, racemates, isomers, and derivatives thereof, shall be considered to be a single Lead Compound.", "size": 2, "snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [48, 60]}, {"key": "exhibit-b", "type": "clause", "offset": [74, 83]}, {"key": "the-steering-committee", "type": "clause", "offset": [122, 144]}, {"key": "in-accordance-with", "type": "clause", "offset": [161, 179]}, {"key": "article-six", "type": "definition", "offset": [180, 191]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [280, 309]}, {"key": "for-purposes-of", "type": "clause", "offset": [311, 326]}, {"key": "net-sales", "type": "clause", "offset": [339, 348]}, {"key": "payments-under-this-agreement", "type": "clause", "offset": [390, 419]}], "hash": "cab6d575048eed000f7443e2a4a2e854", "id": 8}, {"samples": [{"hash": "8PJE1SfoYnb", "uri": "/contracts/8PJE1SfoYnb#lead-compounds", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "236ZVlBhHXt", "uri": "/contracts/236ZVlBhHXt#lead-compounds", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means those Selected Compounds which are designated by SPL as Lead Compounds (pursuant to Section 2.2(b) of the Agreement) for the performance of medicinal chemistry optimization by NeoGenesis.", "size": 2, "snippet_links": [{"key": "selected-compounds", "type": "clause", "offset": [12, 30]}, {"key": "pursuant-to-section", "type": "definition", "offset": [78, 97]}, {"key": "the-agreement", "type": "clause", "offset": [108, 121]}, {"key": "the-performance", "type": "clause", "offset": [127, 142]}], "hash": "0031e7179b9f726f83e00d04d81019e6", "id": 9}, {"samples": [{"hash": "hY4GwfTQfsU", "uri": "/contracts/hY4GwfTQfsU#lead-compounds", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "e9ylXQju5Nm", "uri": "/contracts/e9ylXQju5Nm#lead-compounds", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "means those Selected Compounds which are designated by Schering as Lead Compounds (pursuant to Section 2.2(b) of the Agreement) for the performance of medicinal chemistry optimization by NeoGenesis.", "size": 2, "snippet_links": [{"key": "selected-compounds", "type": "clause", "offset": [12, 30]}, {"key": "pursuant-to-section", "type": "definition", "offset": [83, 102]}, {"key": "the-agreement", "type": "clause", "offset": [113, 126]}, {"key": "the-performance", "type": "clause", "offset": [132, 147]}], "hash": "ef765643a669e4ff734b14251aa8ee69", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXbGVhZC1jb21wb3VuZHMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means not more than two Compounds from each Program \u2014 Primary or Alternate - for which a Testing Request is delivered, none of which are a Development Candidate, which meet the following criteria: (i) the Compound(s) have been selected by Vertex from the Primary Program and/or the Alternate Program, as relevant to the Testing Request (assuming CFFT has not terminated the Alternate Program under the provisions of Section 10.5.3 hereof); (ii) each Compound will be representative of those Compounds in each Program which Vertex believes to be the most promising as potential Drug Products; and", "title": "Lead Compounds", "size": 52, "id": "lead-compounds", "examples": ["If with respect to a Collaboration Program, the JSC determines that none of the <strong>Lead Compounds</strong> has met all the applicable Development Candidate Success Criteria, then the JSC will decide whether or not to revise such success criteria (and designate a Development Candidate based on such revised criteria) and/or determine whether additional work will be conducted for one or more <strong>Lead Compounds</strong> to meet the Development Candidate Success Criteria (and will update the Drug Discovery Plan accordingly)."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"], ["development-candidate", "Development Candidate", "Development Candidate"], ["product-candidate", "Product Candidate", "Product Candidate"]], "related_snippets": [], "updated": "2026-01-11T05:42:16+00:00"}, "json": true, "cursor": ""}}